Viral vaccines and viral vectors used in biotherapeutic applications carry the risk of microbial contamination, which must be addressed.
Anissa Boumlic
Advertisement
Anissa Boumlic, PHD, is associate director EMEA vaccine and viral therapies, MilliporeSigma.
Articles by Anissa Boumlic
Advertisement
Latest Updated Articles
Ensuring Viral Safety of Viral Vaccines and VectorsPublished: September 1st 2018 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
2
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
3
Everything to Know About Cell and Gene Therapy in 2025
4
In KPMG's CEO Outlook, AI, Regulatory Demands, and Supply Chain Risk Rank High
5
